David Allison PhD

David Allison, Ph.D. joined 5 AM Ventures as a Principal in 2016 and was promoted to Partner in 2018. Previously, Dr. Allison was a Principal at Versant Ventures where he was involved in the firm’s investments in BlueRock Therapeutics, NeuWave (acquired by J&J), Crinetics (NASDAQ: CRNX), Aprea and BioTie (acquired by Acorda). Prior to Versant, Dr. Allison worked with the healthcare team at Split Rock Partners on investments in Ardian (acquired by Medtronic), Twelve (acquired by Medtronic), EBR Systems, and Histogenics (NASDAQ: HSGX). He was previously an Associate at PTV Healthcare Capital, worked in the diagnostics and drug discovery business unit at SurModics and was a National Science Foundation Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory.

Dr. Allison serves on the Boards of Neurogastrx and Ceterix and has been a Board Observer of Crinetics (NASDAQ: CRNX), Impel, Portal, and scPharmaceuticals (NASDAQ: SCPH). Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received a B.S.E in Biomedical Engineering from The University of Iowa. Dr. Allison is based in the San Francisco, CA office.